{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:13:16Z","timestamp":1792422796525,"version":"4.5.0"},"reference-count":38,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/Aims<\/jats:title>\n                    <jats:p>Despite widespread use of combination immunotherapy in advanced liver cancer, reliable biomarkers for baseline risk stratification remain lacking. The inflammatory cytokine interleukin\u20106 has established prognostic relevance in this cancer. We investigated the prognostic value of interleukin\u20106 and developed a combined score (ALBI\u20106) integrating interleukin\u20106 with albumin\u2013bilirubin grade, a marker of liver function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this multicentre retrospective cohort study, 216 patients with advanced hepatocellular carcinoma treated with first\u2010line atezolizumab plus bevacizumab were analysed. Interleukin\u20106 was measured at baseline, first response, best response, and progression. The cohort was randomly divided into a training set (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200998) and a validation set (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200990). ALBI\u20106 was derived using Cox regression and evaluated against several established prognostic scores.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Elevated baseline interleukin\u20106 was consistently associated with worse overall survival and remained independently prognostic after adjustment for tumour and clinical factors (extrahepatic spread, vascular invasion, alpha\u2010fetoprotein, performance status, liver function class). In the validation cohort, ALBI\u20106 achieved a concordance index of 0.716 and separated patients into three risk groups with significantly different survival (log\u2010rank\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002); ALBI\u20106 was significantly more discriminative than one comparator score (modified albumin\u2013bilirubin grade,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.040), with numerically higher performance than the remaining comparators. In a separate analysis of the full cohort, ALBI\u20106 significantly outperformed the CRAFITY score at all assessed time points. Bootstrap validation confirmed model stability.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ALBI\u20106 integrates systemic inflammation and liver function into a simple composite index enabling meaningful risk stratification in patients with advanced hepatocellular carcinoma treated with immunotherapy. Prospective external validation is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/apt.71012","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:30:07Z","timestamp":1791520207000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["<scp>ALBI<\/scp>\n                    \u20106\u2014A Novel Prognostic Score Combining\n                    <scp>ALBI<\/scp>\n                    and Interleukin\u20106 in Patients With\n                    <scp>HCC<\/scp>\n                    Treated With Atezolizumab and Bevacizumab"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8133-4536","authenticated-orcid":false,"given":"Paula","family":"Bark","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I University Medical Centre of the Johannes Gutenberg\u2010University Mainz  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5431-4750","authenticated-orcid":false,"given":"Lucas","family":"Wiesmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I University Medical Centre of the Johannes Gutenberg\u2010University Mainz  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Johannes","family":"Gairing","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I University Medical Centre of the Johannes Gutenberg\u2010University Mainz  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kateryna","family":"Shmanko","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I University Medical Centre of the Johannes Gutenberg\u2010University Mainz  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8626-4044","authenticated-orcid":false,"given":"Lukas","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology University Medical Centre of the Johannes Gutenberg\u2010University Mainz  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1397-0682","authenticated-orcid":false,"given":"Maximilian","family":"Moos","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology University Medical Centre of the Johannes Gutenberg\u2010University Mainz  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"St\u00f6hr","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology University Medical Centre of the Johannes Gutenberg\u2010University Mainz  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Graafen","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology University Medical Centre of the Johannes Gutenberg\u2010University Mainz  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"Emrich","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology University Medical Centre of the Johannes Gutenberg\u2010University Mainz  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5122-9014","authenticated-orcid":false,"given":"Felix","family":"Hahn","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology University Medical Centre of the Johannes Gutenberg\u2010University Mainz  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Pinto","family":"dos Santos","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology University Medical Centre of the Johannes Gutenberg\u2010University Mainz  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4904-5133","authenticated-orcid":false,"given":"Bernhard","family":"Scheiner","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine III Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3814-3575","authenticated-orcid":false,"given":"Victoria Berit","family":"Berger","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine III Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7260-532X","authenticated-orcid":false,"given":"Matthias","family":"Pinter","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine III Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Zarka","sequence":"additional","affiliation":[{"name":"Division of Hepatology, Department of Medicine II University Hospital Wuerzburg  Wuerzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3807-1456","authenticated-orcid":false,"given":"Florian P.","family":"Reiter","sequence":"additional","affiliation":[{"name":"Division of Hepatology, Department of Medicine II University Hospital Wuerzburg  Wuerzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Geier","sequence":"additional","affiliation":[{"name":"Division of Hepatology, Department of Medicine II University Hospital Wuerzburg  Wuerzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9681-2542","authenticated-orcid":false,"given":"Najib Ben","family":"Khaled","sequence":"additional","affiliation":[{"name":"Department of Medicine II University Hospital, Ludwig Maximilian University Munich  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0215-9977","authenticated-orcid":false,"given":"Alexander","family":"Philipp","sequence":"additional","affiliation":[{"name":"Department of Medicine II University Hospital, Ludwig Maximilian University Munich  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Springfeld","sequence":"additional","affiliation":[{"name":"Institute of Pathology Heidelberg University Hospital  Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4072-8167","authenticated-orcid":false,"given":"Aurelie","family":"Tomczak","sequence":"additional","affiliation":[{"name":"Institute of Pathology Heidelberg University Hospital  Heidelberg Germany"},{"name":"Liver Cancer Centre Heidelberg  Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1926-4204","authenticated-orcid":false,"given":"Michael T.","family":"Dill","sequence":"additional","affiliation":[{"name":"Liver Cancer Centre Heidelberg  Heidelberg Germany"},{"name":"Department of Gastroenterology, Hepatology, Infectious Diseases and Intoxications Heidelberg University Hospital  Heidelberg Germany"},{"name":"German Cancer Research Centre (DKFZ) Heidelberg Experimental Hepatology, Inflammation and Cancer  Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Scholz","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery University Medical Centre of the Johannes Gutenberg\u2010University Mainz  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Mittler","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery University Medical Centre of the Johannes Gutenberg\u2010University Mainz  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hauke","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery University Medical Centre of the Johannes Gutenberg\u2010University Mainz  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4857-1561","authenticated-orcid":false,"given":"Beate Katharina","family":"Straub","sequence":"additional","affiliation":[{"name":"Institute of Pathology University Medical Centre of the Johannes Gutenberg\u2010University Mainz  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5492-4792","authenticated-orcid":false,"given":"Roman","family":"Kloeckner","sequence":"additional","affiliation":[{"name":"Institute of Interventional Radiology University Hospital Schleswig\u2010Holstein  L\u00fcbeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"B\u00e4uerle","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology University Medical Centre of the Johannes Gutenberg\u2010University Mainz  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Markus","family":"Lange","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I University Medical Centre of the Johannes Gutenberg\u2010University Mainz  Mainz Germany"},{"name":"Department of Medicine II University Hospital, Ludwig Maximilian University Munich  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-1716","authenticated-orcid":false,"given":"Arndt","family":"Weinmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I University Medical Centre of the Johannes Gutenberg\u2010University Mainz  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Robert","family":"Galle","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I University Medical Centre of the Johannes Gutenberg\u2010University Mainz  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Foerster","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I University Medical Centre of the Johannes Gutenberg\u2010University Mainz  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"issue":"7","key":"e_1_2_14_2_1","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1158\/1078-0432.CCR-20-3407","article-title":"FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients With Advanced Unresectable or Metastatic Hepatocellular Carcinoma","volume":"27","author":"Casak S. J.","year":"2021","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"20","key":"e_1_2_14_3_1","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn R. S.","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"10360","key":"e_1_2_14_4_1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular Carcinoma","volume":"400","author":"Vogel A.","year":"2022","journal-title":"Lancet (London, England)"},{"issue":"15","key":"e_1_2_14_5_1","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update","volume":"42","author":"Gordan J. D.","year":"2024","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"14","key":"e_1_2_14_6_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411471","article-title":"Immune System and Hepatocellular Carcinoma (HCC): New Insights Into HCC Progression","volume":"24","author":"Kotsari M.","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"e_1_2_14_7_1","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated Efficacy and Safety Data From IMbrave150: Atezolizumab Plus Bevacizumab vs. Sorafenib for Unresectable Hepatocellular Carcinoma","volume":"76","author":"Cheng A.\u2010L.","year":"2022","journal-title":"Journal of Hepatology"},{"issue":"15","key":"e_1_2_14_8_1","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular Carcinoma","volume":"380","author":"Villanueva A.","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"19","key":"e_1_2_14_9_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17193105","article-title":"Decision\u2010Making Biomarkers Guiding Therapeutic Strategies in Hepatocellular Carcinoma: From Prediction to Personalized Care","volume":"17","author":"Liu D.","year":"2025","journal-title":"Cancers"},{"issue":"4","key":"e_1_2_14_10_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14040883","article-title":"Interleukin\u20106 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated With Combined Immunotherapy","volume":"14","author":"Myojin Y.","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"e_1_2_14_11_1","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jhep.2020.07.026","article-title":"Association of Inflammatory Biomarkers With Clinical Outcomes in Nivolumab\u2010Treated Patients With Advanced Hepatocellular Carcinoma","volume":"73","author":"Sangro B.","year":"2020","journal-title":"Journal of Hepatology"},{"issue":"10","key":"e_1_2_14_12_1","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016295","article-title":"IL\u20106 in Inflammation, Immunity, and Disease","volume":"6","author":"Tanaka T.","year":"2014","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"8","key":"e_1_2_14_13_1","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular Correlates of Clinical Response and Resistance to Atezolizumab in Combination With Bevacizumab in Advanced Hepatocellular Carcinoma","volume":"28","author":"Zhu A. X.","year":"2022","journal-title":"Nature Medicine"},{"key":"e_1_2_14_14_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1599143","article-title":"On\u2010Treatment Modified Glasgow Prognostic Score (mGPS) in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab Provides Prognostic Information","volume":"16","author":"Hattenhauer T.","year":"2025","journal-title":"Frontiers in Immunology"},{"issue":"6","key":"e_1_2_14_15_1","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence\u2010Based Approach\u2010The ALBI Grade","volume":"33","author":"Johnson P. J.","year":"2015","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"3","key":"e_1_2_14_16_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2024.101295","article-title":"Evaluation of Prognostic Scores in Patients With HCC Undergoing First\u2010Line Immunotherapy With Atezolizumab and Bevacizumab","volume":"7","author":"Gairing S. J.","year":"2025","journal-title":"JHEP Reports Innovation in Hepatology"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.4274\/nkmj.galenos.2024.93898"},{"issue":"5","key":"e_1_2_14_18_1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/17474124.2020.1748010","article-title":"ALBI Versus Child\u2010Pugh in Predicting Outcome of Patients With HCC: A Systematic Review","volume":"14","author":"Peng Y.","year":"2020","journal-title":"Expert Review of Gastroenterology & Hepatology"},{"issue":"2","key":"e_1_2_14_19_1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/CIRCULATIONAHA.114.014508","article-title":"Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD Statement","volume":"131","author":"Collins G. S.","year":"2015","journal-title":"Circulation"},{"issue":"10","key":"e_1_2_14_20_1","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/sim.4154","article-title":"On the C\u2010Statistics for Evaluating Overall Adequacy of Risk Prediction Procedures With Censored Survival Data","volume":"30","author":"Uno H.","year":"2011","journal-title":"Statistics in Medicine"},{"issue":"1","key":"e_1_2_14_21_1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.0006-341X.2005.030814.x","article-title":"Survival Model Predictive Accuracy and ROC Curves","volume":"61","author":"Heagerty P. J.","year":"2005","journal-title":"Biometrics"},{"key":"e_1_2_14_22_1","unstructured":"R: The R Project for Statistical Computing https:\/\/www.r\u2010project.org\/."},{"key":"e_1_2_14_23_1","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau T. M.","year":"2000"},{"issue":"30","key":"e_1_2_14_24_1","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1002\/sim.5958","article-title":"Estimating and Comparing Time\u2010Dependent Areas Under Receiver Operating Characteristic Curves for Censored Event Times With Competing Risks","volume":"32","author":"Blanche P.","year":"2013","journal-title":"Statistics in Medicine"},{"key":"e_1_2_14_25_1","unstructured":"A.Kassambara M.Kosinski andP.Biecek \u201cCRAN: Contributed Packages \u201d(2016)."},{"key":"e_1_2_14_26_1","doi-asserted-by":"crossref","DOI":"10.1201\/9781138384484","volume-title":"Medical Risk Prediction","author":"Gerds T. A.","year":"2021"},{"key":"e_1_2_14_27_1","unstructured":"S.Potapov W.Adler M.Schmid andF.Bertrand \u201cCRAN: Contributed Packages \u201d(2011)."},{"key":"e_1_2_14_28_1","unstructured":"J. F. E.Harrell \u201cCRAN: Contributed Packages \u201d(2003)."},{"issue":"3","key":"e_1_2_14_29_1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ebmental-2020-300162","article-title":"TableOne: An Online Web Application and R Package for Summarising and Visualising Data","volume":"23","author":"Panos A.","year":"2020","journal-title":"Evidence\u2010Based Mental Health"},{"issue":"1","key":"e_1_2_14_30_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2025.102138","article-title":"Serum IL\u20106 Is a Prognostic Biomarker for Advanced Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab","volume":"31","author":"Kocheise L.","year":"2025","journal-title":"Annals of Hepatology"},{"issue":"4","key":"e_1_2_14_31_1","first-page":"277","article-title":"The Usefulness of Serum Interleukin\u20106 as a Predictor of Response to Atezolizumab Plus Bevacizumab Combination Treatment in Hepatocellular Carcinoma","volume":"103","author":"Mukozu T.","year":"2025","journal-title":"Oncology"},{"issue":"3","key":"e_1_2_14_32_1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00535-024-02185-w","article-title":"Serum IL\u20106 Concentration Is a Useful Biomarker to Predict the Efficacy of Atezolizumab Plus Bevacizumab in Patients With Hepatocellular Carcinoma","volume":"60","author":"Miura R.","year":"2025","journal-title":"Journal of Gastroenterology"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.10.020"},{"issue":"4","key":"e_1_2_14_34_1","doi-asserted-by":"crossref","DOI":"10.1002\/cnr2.2042","article-title":"Clinical Usefulness of Newly Developed Prognostic Predictive Score for Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma","volume":"7","author":"Ohama H.","year":"2024","journal-title":"Cancer Reports (Hoboken, N.J.)"},{"issue":"12","key":"e_1_2_14_35_1","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00535-024-02150-7","article-title":"CRAFITY Score as a Predictive Marker for Refractoriness to Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicentre Retrospective Study","volume":"59","author":"Ueno M.","year":"2024","journal-title":"Journal of Gastroenterology"},{"key":"e_1_2_14_36_1","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/HEP.0000000000001444","article-title":"Development and Validation of a Risk Prediction Model for Patients With Hepatocellular Carcinoma Receiving Atezolizumab\u2010Bevacizumab","volume":"83","author":"Nam H.","year":"2025","journal-title":"Hepatology"},{"issue":"2","key":"e_1_2_14_37_1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2021.09.035","article-title":"Prognosis of Patients With Hepatocellular Carcinoma Treated With Immunotherapy\u2013Development and Validation of the CRAFITY Score","volume":"76","author":"Scheiner B.","year":"2022","journal-title":"Journal of Hepatology"},{"issue":"10","key":"e_1_2_14_38_1","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1159\/000537965","article-title":"Remaining Issues Related to Serum Cytokines in Patients With Unresectable Hepatocellular Carcinoma Treated by Atezolizumab Plus Bevacizumab Combination Treatment","volume":"102","author":"Nagai H.","year":"2024","journal-title":"Oncology"},{"issue":"10","key":"e_1_2_14_39_1","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1111\/jgh.16672","article-title":"Serum Interleukin\u20106 Levels at the Start of the Second Course of Atezolizumab Plus Bevacizumab Therapy Predict Therapeutic Efficacy in Patients With Advanced Hepatocellular Carcinoma: A Multicentre Analysis","volume":"39","author":"Suzuki T.","year":"2024","journal-title":"Journal of Gastroenterology and Hepatology"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.71012","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/apt.71012","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.71012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:30:15Z","timestamp":1791520215000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.71012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":38,"alternative-id":["10.1111\/apt.71012"],"URL":"https:\/\/doi.org\/10.1111\/apt.71012","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"2026-06-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"apt.71012"}}